Compositions and Treatments for Haemophilus Influenzae

Title: Compositions and Treatments for Haemophilus Influenzae

Invention: This invention involves the generation, manipulation and administration of a non-toxic, broadly cross-reactive immunoprotective nontypeable H. influenzae vaccine.

Background: H. Influenzae (Hi) is a Gram-negative anaerobic pathogenic bacterium responsible for causing otitis media (inner ear inflammation) in children. Acute Otitis Media (AOM) is the most common occurring infection resulting from nontypeable Haemophilus Influenzae, resulting in roughly 33% of children’s visits to healthcare clinics. The only current vaccine for Hi specifically treats only Hi type b. The invention presented here is the development of a non-toxic, broadly cross-reactive immunoprotective vaccine composition for treating nontypeable Hi (NTHi) in order to provide a broader and improved immune response to the bacterium.

Applications:

- Biotechnology
- Medical treatment
- Medical condition management
- Pharmaceuticals

Advantages:

- Capable of drastically reducing the incidence rates of AOM resulting from NTHi
- Reduces the physical and financial burden of treating AOM in children
- Provides a non-toxic, broadly cross-reactive immunoprotective and immunostimulant vaccine (for nontypeable H. influenza)

Contact: Rakhi Gibbons  
Asst. Director, Life Sciences  
rakhig@tla.arizona.edu  
(520) 626-6695

The University of Arizona, Tucson, Arizona
Licensing Manager:
Rakhi Gibbons
RakhiG@tla.arizona.edu
(520) 626-6695

Inventors
Thomas Seale
Paul Whitby
Research Associate Professor, Child Health
Daniel Morton
Research Associate Professor, Phx Children's Hospital, Child Health
Terrence Stull
SVP Research, Phx Children's Hospital, Child Health